AbbVie的Q2收入略微漏掉了估计数,但收入逐年增加6.6%。 AbbVie's Q2 earnings slightly missed estimates, but revenue rose 6.6% year-over-year.

AbbVie Inc.报告,第二季度收入为每股2.97美元,略低于估计数,尽管收入逐年增长6.6%,达到15.42亿美元。 AbbVie Inc. reported second-quarter earnings of $2.97 per share, slightly below estimates, though revenue rose 6.6% year-over-year to $15.42 billion. 股票交易额接近223.09美元,市场上限为394.09亿美元,物价对收益比率为106.23。 The stock, trading near $223.09, has a market cap of $394.09 billion and a price-to-earnings ratio of 106.23. 尽管股息支付比率高达312.38%,但AbbVie宣布季度股息为每股1.64美元,收益为2.9%。 Despite a high dividend payout ratio of 312.38%, AbbVie declared a quarterly dividend of $1.64 per share, yielding 2.9%. 机构投资者减少了股权,阿根廷投资公司和福特资本公司减少了股权,而Bfsg投资公司和芝加哥信托公司增加了股权. Institutional investors reduced stakes, with Argentarii LLC and Forte Capital LLC trimming holdings, while Bfsg LLC and CHICAGO TRUST Co NA increased theirs. 执行副总裁在8月出售了大量股份。 Executive vice presidents sold significant shares in August. 分析师维持“机动购买”共识评级,目标价格为223.45美元。 Analysts maintain a "Moderate Buy" consensus rating with a target price of $223.45. 该公司以Humira和Skyrizi等毒品闻名,其低贝塔为0.53,股本回报率强劲,为699.66%。 The company, known for drugs like Humira and Skyrizi, has a low beta of 0.53 and a strong return on equity of 699.66%.